```
1
       IN THE UNITED STATES DISTRICT COURT
        FOR THE NORTHERN DISTRICT OF OHIO
3
                EASTERN DIVISION
4
5
     IN RE: NATIONAL
                             : HON. DAN A.
     PRESCRIPTION OPIATE
                            : POLSTER
     LITIGATION
7
     APPLIES TO ALL CASES : NO.
8
                              1:17-MD-2804
9
            - HIGHLY CONFIDENTIAL -
10
    SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
11
12
                January 10, 2019
13
14
15
                 Videotaped deposition of
    FRANK DEVLIN, taken pursuant to
16
    notice, was held at the offices of
    Zuckerman Spaeder, LLP, 1800 M Street NW,
    Suite 1000, Washington, D.C., beginning
17
    at 8:33 a.m., on the above date, before
18
    Michelle L. Gray, a Registered
    Professional Reporter, Certified
19
    Shorthand Reporter, Certified Realtime
    Reporter, and Notary Public.
20
21
22
           GOLKOW LITIGATION SERVICES
        877.370.3377 ph | 917.591.5672 fax
23
                 deps@golkow.com
2.4
```

```
APPEARANCES:
2
3
    BAKER & BAKER, PLLC
    BY: WILLIAM C. BAKER, JR., ESQ.
4
    300 East Government Street
    Pensacola, Florida 32502
5
    (850) 433-0888
    Wcb850@gmail.com
6
    Smh@bakerlawemail.com
7
           - and -
8
    WEISMAN KENNEDY & BERRIS, LPA
    BY: JAMES A. DEROCHE, ESQ.
9
    101 West Prospect Avenue, Suite 1600
    Midland Building
10
    Cleveland, Ohio 44115
    (216) 696-7009
11
    Jderoche@garson.com
    Representing the Plaintiffs
12
13
    ZUCKERMAN SPAEDER, LLP
    BY: ALEXANDRA W. MILLER, ESQ.
14
    1800 M. Street NW, Suite 1000
    Washington, D.C. 20036
15
    (202) 778-1845
    smiller@zuckerman.com
16
    Representing the Defendant, CVS, and the
    Witness
17
18
    WILLIAMS & CONNOLLY, LLP
    BY: KATELYN ADAMS, ESQ.
19
    725 12th Street, NW
    Washington, D.C. 20005
20
    (202) 434-5148
    kadams@wc.com
21
    Representing the Defendant, Cardinal
    Health
22
23
2.4
```

```
TELEPHONIC APPEARANCES:
2.
    MOTLEY RICE, LLC
3
    BY: MICHAEL ELSNER, ESO.
    28 Bridgeside Boulevard
    Mount Pleasant, South Carolina 29464
    (843) 216-9373
5
    melsner@motleyrice.com
    Representing the Plaintiffs
6
7
    JONES DAY
    BY: CHRISTINE D. PROROK, ESQ.
    77 West Wacker Drive
8
    Chicago, Illinois 60601
9
    (312) 269-4113
    Cprorok@jonesday.com
10
    Representing the Defendant, Walmart
11
    ARNOLD & PORTER KAYE SCHOLER, LLP
12
    BY: ZENO HOUSTON, ESQ.
    250 West 55th Street
13
    New York, New York 10019
    (212) 836-7332
14
    Zeno.houston@arnoldporter.com
    Representing the Defendants, Endo Health
15
    Solutions; Endo Pharmaceuticals, Inc.;
    Par Pharmaceutical Companies, Inc. f/k/a
16
    Par Pharmaceutical Holdings, Inc.
17
    JACKSON KELLY, PLLC
18
    BY: JONATHAN L. ANDERSON, ESO.
    500 Lee Street East
19
    Suite 1600
    Charleston West Virginia 25301
20
    (304) 340-1169
    Jlanderson@jacksonkelly.com
21
    Representing the Defendant,
    AmerisourceBergen
22
23
2.4
```

```
1
    ALSO PRESENT:
    Stephanie Heckman, Paralegal
2
    (Baker & Baker, PLLC)
3
4
    Justin L. Mann, Esq. (Law Clerk)
    (Ropes Gray - via telephone)
5
6
    Amy Kennedy, Paralegal
    (Weisman Kennedy - via telephone))
7
8
    VIDEOTAPE TECHNICIAN:
9
    Dan Lawlor
10
    LITIGATION TECHNICIAN:
11
    James Beall
12
13
14
15
16
17
18
19
20
21
22
23
24
```

```
1
2
                      INDEX
3
4
    Testimony of:
5
                  FRANK DEVLIN
6
7
           By Mr. Baker
                                          14
8
           By Mr. DeRoche
                                          384
9
10
11
12
                   EXHIBITS
13
14
15
    NO.
                  DESCRIPTION
                                          PAGE
16
    CVS
17
    Devlin-P-18 E-mail Thread
                                          89
                  1/3/08
                  Subject, New Rx
18
                  DEA SOP
19
                  CVS-MDLT1-000025204-59
20
    CVS
    Devlin-P-48 Controlled Drug
                                          96
21
                  DEA Standard
                  Operating Procedures
22
                  Manual
                  CVS-MDLT1-000024877-41
23
24
```

1		-	
2	F. X	HIBITS (Cont'd.)
3			,
4			
5	NO.	DESCRIPTION	PAGE
6	CVS		
7 8	Devlin-P-53	E-mail, 10/8/12 Subject, Conference Call Notes CVS-MDLT1-000033579-83	343
9	CTIC	CVS-MDL11-000033579-6.	1
	CVS Devlin-P-55	Business Idea	321
10		Description CVS-MDLT1-000034175-7	
11			
	CVS		
12	Devlin-P-56	Memo, 8/13/10 Subject, Control	212
13		Drug IRR Update CVS-MDLT1-000034183	
14		CAR WITH 000024102	
	CVS		
15		E-mail Thread 5/19/09	92
16		Subject, Updated DEA SOP	
17		CVS-MDLT1-000034234-3	5
18	CVS		
19	Devlin-P-64	Drug Fact Sheet Heroin CVS-MDLT1-000055613-30	71 6
20			
21	CVS		
22	Devlin-P-68	E-mail, 5/16/11 Subject, Control Drug Suspicious Order	226
23		Monitoring CVS-MDLT1-000057736-3	7
24			,

```
1
2
             EXHIBITS (Cont'd.)
3
4
5
    NO.
                 DESCRIPTION
                                        PAGE
6
    CVS
    Devlin-P-68A E-mail Thread
                                        243
7
                 1/28/11
                 Subject, IRR
8
                 Narratives
                 CVS-MDLT1-000083966-71
9
    CVS
10
    Devlin-P-69 SOM Due Diligence
                                        282
                 Guidance Document
11
                 CVS-MDLT-000057741-43
12
    CVS
                 E-mail, 8/25/10
    Devlin-P-70
                                        109
13
                 Subject, Control Drug
                 IRR Draft 3
14
                 CVS-MDLT1-000057751-54
15
    CVS
    Devlin-P-71 E-mail Thread
                                        159
16
                 3/14/11
                 Subject, IRR/SOM
                 Retunement BSR_LOG
17
                 CVS-MDLT1-000057759
18
                 CVS-MDLT1-000055834
19
    CVS
    Devlin-P-81 E-mail Thread
                                      137
20
                 9/1/10
                 Subject, DEA
21
                 Speaking Points
                 CVS-MDLT1-000075299-12
22
23
24
```

```
1
2
             EXHIBITS (Cont'd.)
3
4
5
    NO.
                 DESCRIPTION
                                        PAGE
6
    CVS
    Devlin-P-82 E-mail Thread
                                        327
7
                 10/12/10
                 Subject, VBDC
8
                 Ouestion
                 CVS-MDLT1-000075542
9
    CVS
10
    Devlin-P-92 E-mail Thread
                                        331
                 11/29/12
11
                 Subject, Privileged
                 And Confidential
12
                 SOM Process Documentation
                 CVS-MDLT1-000083064-66
13
    CVS
14
    Devlin-P-94 E-mail Thread
                                        96
                 11/5/09
                 Re: 11/10/09
15
                 CVS-MDLT-000087889-90
16
    CVS
17
                 E-mail Thread
    Devlin-P-95
                                         212
                 7/26/10
                 Subject, SOM Update
18
                 CVS-MDLT1-000088522-34
19
    CVS
    Devlin-P-97 E-mail, 8/28/10
20
                                        114
                 Subject, DEA SOP
21
                 8/25/10
                 CVS-MDLT1-000088956-25
22
23
24
```

```
1
2
             EXHIBITS (Cont'd.)
3
4
5
    NO.
                 DESCRIPTION
                                         PAGE
6
    CVS
    Devlin-P-98 E-mail Thread
                                         102
7
                  8/23/10
                  Subject, DEA SOP
8
                  CVS-MDLT-000089188
9
    CVS
    Devlin-P-102 E-mail, 2/21/08
                                         76
10
                  Subject, DEA Letters
                  SOMs
11
                  CVS-MDLT1-000091508-18
12
    CVS
                                         59
    Devlin-P-104 E-mail Thread
13
                  1/18/13
                  Subject, 1/18/13
14
                  CVS-MDLT1-000103329
15
    CVS
    Devlin-P-106 E-mail Thread
                                         356
16
                  11/27/12
                  Subject, SOM Meeting
17
                  11/27
                  CVS-MDLT1-000029867-68
18
    CVS
19
    Devlin-P-130 LinkedIn Profile
                                         26
                 Frank Devlin
20
    CVS
21
    Devlin-P-131 CVS Health
                                         29
                 Web Printout
22
                  History
23
24
```

```
1
2
             EXHIBITS (Cont'd.)
3
4
5
    NO.
                 DESCRIPTION
                                         PAGE
6
    CVS
    Devlin-P-132 Distribution Center
                                        38
7
                 ID XREF
                 CVS Caremark Suppliers
8
9
    CVS
    Devlin-P-140 Suspicious Order
                                        285
10
                 Monitoring
                 For PSE/Control
11
                 Drugs
                 8/27/10
12
                 CVS-MDLT1-000061191-03
13
    CVS
    Devlin-P-143 E-mail, 10/13/10
                                         148
14
                 Subject, LP Analyst
                 CVS-MDLT1-000104894-97
15
    CVS
16
    Devlin-P-146 Letter, 3/22/07
                                         196
                 Subject, Regulatory
17
                 Consulting Services
                  (Buzzeo PDMA)
18
                 CVS-MDLT1-00109199-06
19
    CVS
    Devlin-P-150 E-mail Thread
                                         200
20
                 2/9/11
                 Subject, The CVS Retunement
21
                 CVS-MDLT1-000061141-42
22
    CVS
    Devlin-P-164 Chart, Native
                                         323
23
                 Document Yes, No, Code
                  (No Bates)
24
```

```
1
2
             EXHIBITS (Cont'd.)
3
4
5
    NO.
                 DESCRIPTION
                                         PAGE
6
    CVS
    Devlin-P-200 Item Review
                                         469
7
                  Reports
                  CVS-MDLT1-00001195-04
8
    CVS
9
    Devlin-P-201 Item Review
                                         426
                  Reports
10
                  CVS-MDLT1-000100763-74
11
    CVS
    Devlin-P-209 E-mail, 1/6/10
                                         315
12
                  Subject, Control Drug
                  IRR Issue Recap
13
                  CVS-MDLT1-000110260
14
    CVS
    Devlin-P-211 E-mail Thread
                                        270
15
                  2/24/10
                  Subject, Adjustment
16
                  To the CVS SOM
                  CVS-MDLT1-000110434-36
17
18
19
20
21
22
23
24
```

```
1
2
              DEPOSITION SUPPORT INDEX
3
4
    Direction to Witness Not to Answer
5
6
    PAGE LINE
    None.
7
    Request for Production of Documents
8
9
    PAGE
            LINE
    None.
10
11
    Stipulations
12
    PAGE LINE
    None.
13
    Questions Marked
14
    PAGE LINE
15
    None.
16
17
18
19
20
21
22
23
24
```

1	THE VIDEOGRAPHER: We are
2	now on the record.
3	My name is Dan Lawlor, I'm a
4	videographer with Golkow
5	Litigation Services.
6	Today's date is January 10,
7	2019, and the time is 8:33 a.m.
8	This video deposition is
9	being held in Washington, DC, in
10	the matter of National
11	Prescription Opiate litigation,
12	MDL Number 2804.
13	The deponent is Frank
14	Devlin.
15	Counsel will be noted on the
16	stenographic record.
17	The court reporter is
18	Michelle Gray and will now swear
19	in the witness.
20	
21	FRANK DEVLIN,
22	having been first duly sworn, was
23	examined and testified as follows:
24	

1 EXAMINATION 2 3 BY MR. BAKER: 4 Q. Please state your name. 5 Frank Devlin. Α. 6 Mr. Devlin, where do you 0. 7 live? 8 I live in Pocasset, Α. 9 Massachusetts. 10 What is your employment 0. 11 right now? 12 Α. Excuse me? 13 Where are you employed right 0. 14 now? 15 I own my own consulting Α. 16 company. 17 What's the name of the 0. 18 company? 19 Seashore Risk Management. Α. 20 And what is the nature of 0. 21 that business? 22 It's a consulting firm Α. 23 focusing on safety, OSHA compliance, auditing, forklift training. 24

- 1 Are your customers corporate Q. 2 customers? 3 A. Yes. 4 Is CVS one of your 0. 5 customers? 6 No. Α. 7 Have you courted CVS to be Ο. 8 one of your customers? 9 MS. MILLER: Object to form. 10 BY MR. BAKER: 11 Have you tried to get CVS to 12 become one of your customers? 13 MS. MILLER: Objection. 14 BY MR. BAKER: 15 O. Go ahead. 16 A. No. 17 Have you made any contact 0. 18 with CVS since leaving CVS in 2012? 19 Α. No. 20 What was the reason you left 0. 21 CVS in 2012? 22 A better employment

 - 23 opportunity.
 - 24 Q. What was the better

- employment opportunity?
- A. Amazon.
- Q. Is that where Mr. Burtner
- ⁴ also went to work, Aaron Burtner?
- ⁵ A. Yes.
- 6 Q. Okay. Did -- did you help
- ⁷ Mr. Burtner get employed at Amazon?
- MS. MILLER: Object to form.
- 9 BY MR. BAKER:
- Q. Did you?
- MS. MILLER: Object.
- 12 BY MR. BAKER:
- 0. Go ahead.
- Let me explain. When the
- attorney objects, she objects to form.
- 16 That doesn't mean you can't answer the
- question. It's just a technicality in
- the rules of procedure where she says
- object to form, so she preserves the
- right to go to the judge and have the
- question looked at by the judge to
- determine if it's a properly phrased
- question. And -- but it doesn't mean you
- 24 don't answer the question.

```
1
                 So if she instructs you not
2
    to answer, that would be the only time
    you wouldn't answer the question. Fair
4
    enough?
5
                 MS. MILLER: And just,
6
           Frank, that's correct. I'm noting
7
           my objections on the record. You
8
           may respond to the question unless
9
           I instruct you not to answer.
10
                 THE WITNESS: Okay.
11
                 Can you repeat the question?
12
    BY MR. BAKER:
13
                 Yeah, many times during this
14
    deposition counsel seated to your left
    will say object to form. That's her
15
16
    right to do that. That doesn't mean that
17
    you don't answer the question. It's just
18
    noted on the record that she objected to
19
    the question. It doesn't necessarily
20
    mean something's wrong with the question.
21
    It's just she's preserving her right to
22
    object at a later time.
```

- A. I understood.
- Q. Is that clear?

- All right. So what, if any,
- ² contact did you have with Mr. Burtner
- before he came to work for Amazon, after
- 4 you left --
- ⁵ A. Yes.
- 6 Q. -- CVS, you went to Amazon,
- ⁷ right?
- A. That is correct.
- 9 O. In 2012.
- 10 A. That is correct.
- Q. Okay. What contact did you
- have with Mr. Burtner after you left CVS
- to go to Amazon?
- 14 A. I reached out to Mr. Burtner
- 15 for possible employment opportunity with
- 16 Amazon.
- Q. When did you do -- okay.
- When did you do that?
- MS. MILLER: Bill, would you
- just give him a chance to answer?
- MR. BAKER: Sure.
- 22 BY MR. BAKER:
- O. And I didn't mean to
- overstep your answer, but you're --

- you're kind of soft-spoken so I can't
- tell when you're finished your answer.
- THE WITNESS: Okay.
- MS. MILLER: And, Frank,
- 5 give him time to complete his
- question, please.
- ⁷ BY MR. BAKER:
- Q. Are you ready for the
- ⁹ question?
- 10 A. Can you repeat your
- 11 question?
- Q. Okay. The question is, when
- did you reach out to Mr. Burtner for the
- prospect of employment with Amazon when
- you were at Amazon?
- 16 A. It probably would have been
- sometime in 2013. I can't recall the
- 18 exact date.
- 0. All right. And what was the
- reason that you reached out to him?
- MS. MILLER: Object to form.
- THE WITNESS: I knew him and
- I knew his capabilities.
- 24 BY MR. BAKER:

```
Q. Do you know whether or not
```

- ² he expressed anything to you about being
- unhappy at CVS with his employment?
- MS. MILLER: Objection.
- 5 THE WITNESS: No.
- MS. MILLER: Frank, just
- give me a little time, stepping on
- my objections. Go ahead.
- 9 BY MR. BAKER:
- Q. Did Mr. Burtner express to
- you any problems going on within the
- morale of employees at CVS while he was
- 13 there?
- MS. MILLER: Object to form.
- 15 BY MR. BAKER:
- Q. Did he express that to you
- 17 at all?
- MS. MILLER: Object to form.
- THE WITNESS: No, not that I
- can recall.
- 21 BY MR. BAKER:
- Q. How long did you work at
- 23 Amazon while Mr. Burtner was also at
- 24 Amazon?

- A. My employment at Amazon was
- from beginning of November 2012 through
- 3 March of 2014.
- Q. I'm going to go through a
- ⁵ list of acronyms which are abbreviations
- 6 for words. And I want to make sure
- ⁷ before we go into your deposition today
- 8 that when we use these acronyms, we're --
- ⁹ we're on the same page with respect to
- these acronyms.
- Okay? Are you with me? Do
- 12 you understand?
- 13 A. I do.
- Q. Okay. All right. The first
- acronym is SOM, can you tell us what SOM
- 16 stands for?
- A. I believe that's suspicious
- 18 order monitoring.
- 19 Q. The next acronym is SOP, can
- you tell us what SOP stands for?
- MS. MILLER: Object to form.
- THE WITNESS: I believe that
- would be standard operating
- procedure.

```
1
    BY MR. BAKER:
2
                 I'm asking you these
3
    questions in reference to how they were
4
    used at CVS. So that's the context of
5
    the question. So at CVS, SOP was
6
    standard operating procedure, correct?
7
                 MS. MILLER: Objection.
8
                 THE WITNESS: I believe so.
9
           I can't say 100 percent. There
10
           are a lot of -- a lot of
11
           abbreviations, whether it was at
12
           CVS or Amazon. So sometimes they
13
           tend to blend together.
14
    BY MR. BAKER:
15
                 When we're talking about an
16
    SOM SOP, would that be a suspicious order
17
    monitoring standard of procedure at CVS
18
    when you were there?
19
                 MS. MILLER: Objection.
20
                  THE WITNESS:
                                No.
21
    BY MR. BAKER:
22
                 Sir? What's the answer?
           0.
23
                 MS. MILLER: Go ahead.
24
                  THE WITNESS:
                                No.
```

```
1
    BY MR. BAKER:
           Q.
2
                 What would an SOM SOP be?
3
                 MS. MILLER: Objection.
4
                 THE WITNESS: I believe it
5
           would be suspicious order
6
           monitoring standard operating
7
           procedure.
8
    BY MR. BAKER:
9
           Q. Okay. When you're talking
10
    about a P&P, is that policy and
11
    procedure?
12
                 MS. MILLER: Objection.
13
                 THE WITNESS: Can you repeat
14
           that?
15
    BY MR. BAKER:
16
              P&P, is that policy and
17
    procedure?
18
                 MS. MILLER: Objection.
19
                 THE WITNESS: I'd have to
20
           see the context in how it's being
21
           used.
22
    BY MR. BAKER:
23
           Q. Okay. DOJ, that's the
24
    Department of Justice. Are you familiar
```

- ¹ with that?
- A. I've heard the terminology.
- Q. DEA. Who is the DEA that
- 4 you know to exist in the context of your
- ⁵ employment when you worked there at CVS?
- A. That would be the Drug
- ⁷ Enforcement Agency.
- 8 O. FDA, who would that be in
- ⁹ the context of your employment at CVS
- when you worked in the suspicious order
- monitoring department?
- MS. MILLER: Objection.
- MR. BAKER: She objected.
- 14 BY MR. BAKER:
- O. What does FDA mean to you?
- 16 Food and Drug Administration. Do you
- understand that?
- A. I've heard that term used,
- 19 yes.
- Q. Okay. CVS, what does that
- 21 stand for?
- MS. MILLER: Objection.
- THE WITNESS: I've heard it
- stand for a couple different

- terms.
- ² BY MR. BAKER:
- Q. Tell me.
- ⁴ A. For Consumer Value Stores.
- ⁵ Q. Anything else?
- A. Also Convenience Value, and
- ⁷ I forget what the other S was.
- 8 O. C.F.R., Code of Federal
- 9 Regulation, are you familiar with that?
- A. Which one?
- 11 Q. Are you familiar with the
- 12 concept of Code of Federal Regulation?
- 13 Are you familiar with that term?
- 14 A. I've heard the term
- ¹⁵ "C.F.R.," yes.
- O. CSA, Controlled Substances
- 17 Act, have you ever heard of that?
- MS. MILLER: Objection.
- THE WITNESS: I believe I
- may have heard that, yes.
- 21 BY MR. BAKER:
- Q. Okay. When you worked at
- 23 CVS, that was from May of 25 -- May of
- 24 2005 to October of 2012; is that right?

- ¹ A. No.
- Q. When did you work there?
- A. February 11th, 1991, through
- 4 the end of October 2012.
- ⁵ Q. Do you have a LinkedIn page?
- ⁶ A. Yes.
- 7 Q. Let me show you what's been
- 8 marked as Plaintiff's Exhibit Number 130.
- 9 (Document marked for
- identification as Exhibit
- 11 CVS-Devlin-P-130.)
- 12 BY MR. BAKER:
- Q. Is this your LinkedIn page
- that you're looking at?
- 15 A. I need to get my glasses.
- 0. Is that it?
- 17 A. I need to look through it
- 18 first. Appears to be, yes.
- 0. Okay. On your LinkedIn
- page, the second-to-last page, it has CVS
- Health.
- MR. BAKER: Page forward,
- please.
- 24 BY MR. BAKER:

- Q. At the top, it says here
- that you were employed at CVS Health from
- May 2005 to October 2012, seven years and
- 4 six months. Did you enter that data in
- 5 your page?
- ⁶ A. Yes.
- Q. Okay. What was the reason
- 8 that you chose that time frame to tell
- 9 everybody that you were employed at CVS
- Health as opposed to 1991 forward?
- MS. MILLER: Objection.
- THE WITNESS: Just from an
- age standpoint.
- 14 BY MR. BAKER:
- Q. What do you mean an age
- standpoint?
- A. Just there's no requirement
- on LinkedIn as far as putting down exact
- employment dates.
- Q. What happened in May of 2005
- with respect to your employment that
- causes you to choose that date?
- A. I believe at that point, and
- not 100 percent sure that I probably

- would have been promoted to another level
- in a director position.
- Q. What position were you
- 4 promoted to in May of 2005 at CVS Health?
- 5 A. CVS had various levels of
- 6 director positions.
- ⁷ Q. What was the position?
- A. It was a similar position to
- ⁹ what I was already doing.
- 0. What was the name of the
- 11 position?
- 12 A. Director of logistics, loss
- prevention.
- Q. Okay. So at that point you
- 15 continued to work as director of
- logistics, loss prevention from May 2005
- to October 2012; is that right?
- 18 A. Can you repeat that?
- O. Did you work as director of
- logistics, loss prevention from May 2005
- to October 2012 at CVS Health?
- A. Yes.
- Q. Okay. During that time, was
- ²⁴ CVS known as CVS Health or CVS Caremark?

```
1
                 MS. MILLER: Objection.
2
                 THE WITNESS: They were
3
           probably -- they've had so many
4
           different names. It could have
5
           been CVS Caremark.
6
    BY MR. BAKER:
7
           Q. Okay.
8
                  (Document marked for
9
           identification as Exhibit
10
           CVS-Devlin-P-131.)
11
    BY MR. BAKER:
12
                 Let me show you Exhibit 131.
13
    I'm trying to get an accurate history of
14
    the names of the corporations within CVS
15
    Health. And I'd like to spend some time
16
    doing that with you.
17
                  If you could turn -- this
    comes from CVS Health's website. And if
18
19
    you turn to the area of 2001 through
20
           Go about eight pages in.
    2006.
21
                 What was the date again?
           Α.
22
                 2001 at the top of the page.
           Ο.
23
    Do you see it? Are you there?
2.4
                  "CVS introduces ExtraCare
           Α.
```

```
card"?
1
2
           Q. Correct. Okay. Go down to
3
           It says, "CVS Caremark Rx and
    2003.
4
    AdvancePCS announce strategic
5
    combination, creating a $23 billion
6
    company." Were you with them at the
7
    time?
8
                 MS. MILLER: Objection.
9
    BY MR. BAKER:
10
           Q. Were you with CVS Caremark
11
    at the time?
12
                 MS. MILLER: Objection.
13
                 THE WITNESS: I was employed
14
           at CVS from February 11, 1991
15
           through the end of October 2012.
16
    BY MR. BAKER:
17
                 Okay. So 2003 you would
    have been employed by CVS Caremark?
18
19
                 MS. MILLER: Objection.
20
    BY MR. BAKER:
21
           Q. Yes?
22
           Α.
                Yes.
23
           Q. Okay. All right. Then it
```

talks about in 2007, it says, "CVS" -- go

24

```
to the next page. It says, "CVS
```

- ² Corporation and Caremark Rx, Inc.,
- 3 complete their transformative merger,
- 4 creating CVS Caremark, the nation's
- ⁵ premier integrated pharmacy services
- ⁶ provider."
- Is that, to your knowledge,
- when CVS became known as CVS Caremark?
- 9 MS. MILLER: Objection.
- 10 BY MR. BAKER:
- 11 Q. Or not?
- MS. MILLER: Objection.
- THE WITNESS: That's what
- this document says. I wouldn't
- know that.
- 16 BY MR. BAKER:
- Q. Who was your employer in
- 18 2007 at CVS, which CVS entity?
- MS. MILLER: Objection.
- THE WITNESS: I just refer
- to CVS as CVS.
- 22 BY MR. BAKER:
- ²³ Q. Okay.
- A. I didn't get -- I didn't get

- 1 kind of hung up as far as whether it's
- ² CVS Pharmacy, CVS Distribution, CVS
- 3 Logistics, CVS Health, CVS Caremark.
- 4 It's CVS.
- Okay. Do you know when the
- 6 corporation became known as CVS Health?
- MS. MILLER: Objection.
- 8 THE WITNESS: No.
- 9 BY MR. BAKER:
- Q. Okay. Go to 2014, under the
- 11 history of the company.
- MS. MILLER: Mr. Baker, just
- a question about the document.
- Where was this obtained
- 15 from?
- MR. BAKER: From the
- website, CVS.com. It says it
- right there at the top.
- 19 BY MR. BAKER:
- Q. You see on the page under
- 2014, do you see that? You're there.
- 22 2014. Go to the next page.
- A. It's cut off.
- Q. Go to the next page. Go

- about a third of the way down the page.
- ² It says, "CVS Caremark announces that its
- 3 corporate name has changed to CVS Health
- 4 to further reflect its broader commitment
- 5 to healthcare."
- Do you see that?
- ⁷ A. I do.
- Q. Okay. Is that, to your
- 9 knowledge, when CVS Caremark became known
- 10 as CVS Health?
- MS. MILLER: Objection.
- THE WITNESS: I really
- didn't pay attention to it.
- 14 BY MR. BAKER:
- O. Okay. Well, you list CVS
- Health as your employer. That's why I'm
- wondering why you chose that name. Is
- 18 that the last name that the company was
- 19 known as at the time that you left, or
- did it become known as CVS Health after
- you left?
- MS. MILLER: Objection.
- THE WITNESS: The LinkedIn
- page, it's not -- the LinkedIn

```
1
           page isn't, as far as I know it is
2
           not a legal document. And in
3
           putting my history down, it's --
4
           you try to keep current. So it's
5
           not a reflection of -- I didn't
6
           get into -- again, I didn't get
7
           into whether it's CVS, CVS
8
           pharmacy, CVS Health.
9
                 When you update your
10
           LinkedIn page, that comes up, it's
           now referred to as CVS Health.
11
12
    BY MR. BAKER:
13
           Q. Okay. Let me explain. I'm
14
    not criticizing you for putting CVS
15
    Health on there. I just want know the
16
    name of the company that paid you while
17
    you worked there. That's all I'm getting
18
    at. Okay.
19
                 So when you left in 2012,
20
    was the company known as CVS Health or
    CVS Caremark, or do you know?
21
22
                 MS. MILLER: Objection --
23
           objection. Asked and answered.
24
    BY MR. BAKER:
```

- Q. Do you know?
- A. I believe I already answered
- 3 that.
- O. Okay. See, here is what I'm
- 5 asking you. Do you know whether or not
- the company name was CVS Caremark or CVS
- ⁷ Health when you left, do you know?
- 8 That's all I'm asking.
- 9 MS. MILLER: Objection.
- 10 Asked and answered.
- THE WITNESS: No.
- 12 BY MR. BAKER:
- 0. Okay. You don't know.
- 14 Okay.
- So when you worked there as
- director of logistics loss prevention,
- how many -- or excuse me. Where
- 18 physically were you located when you were
- working as the director of logistics loss
- prevention in 2005?
- A. 2005. My office may have
- been in the Woonsocket distribution
- center.
- Q. Where were you employed in

- 1 2006, where was your physical location?
- A. It still may have been in
- 3 the distribution center. But I --
- Q. Okay. How long did that
- ⁵ continue?
- A. Probably, I don't know, it
- ⁷ was 2007, 2008 I moved to the corporate
- 8 office which was just up the street.
- 9 Q. Okay. So -- and from 2008
- all the way through the time that you
- 11 left in 2012, were you in the corporate
- office in Woonsocket, Rhode Island?
- 13 A. Yes. Various -- various
- 14 locations. I was 1 CVS Drive. I was
- 15 also at the --
- Q. Let me show you what's
- marked as Exhibit 130 --
- A. I didn't finish.
- 19 Q. Yeah, go ahead. I'm just
- trying to move through this, because we
- only have a certain amount of time to do
- 22 this.
- 23 A. Okay.
- Q. I appreciate the fact that

- you're trying to be precise in your
- answers, but if you drag it on beyond
- what's necessary to answer the question,
- 4 it just makes us have to stay here that
- 5 much longer. And I'd really like to move
- through this for your benefit, to catch
- your airplane this afternoon and for
- 8 everybody's benefit. Okay? I'm not
- ⁹ trying to be ugly to you. I just want to
- move through this. Okay?
- A. All right.
- Q. So if we could do that, I'd
- appreciate you doing that in the context
- of your answer.
- A. Sure.
- Q. I know you're nervous. It's
- obvious from looking at you, but I'm not
- trying to do anything other than ask you
- straight questions and get straight
- answers. Is that fair?
- A. Okay. I just want to make
- sure I understand the question.
- Q. Sure. If you -- if you
- think I'm being unfair with you, tell me.

```
Okay? But I'm trying to be very fair
```

- with you in how I treat you --
- A. No, I understand --
- Q. -- and I want to be very
- ⁵ fair with you in terms of letting you
- 6 look at the documentation that I'm
- ⁷ looking at so you understand where I'm
- 8 coming from. I'm just trying to get the
- 9 facts. Is that -- is that clear?
- A. Yes, sir.
- 11 Q. Okay.
- MS. MILLER: And, Bill, just
- give him a chance to answer the
- question.
- MR. BAKER: Sure. Sure.
- 16 (Document marked for
- identification as Exhibit
- 18 CVS-Devlin-P-132.)
- 19 BY MR. BAKER:
- Q. This is marked as
- 21 Exhibit 132. This is --
- A. If I just can go back, I
- wanted to just discuss where my office
- 24 was located.

- O. Sure. Go ahead.
- A. I was 1 CVS Drive, and then
- towards the end of my tenure we moved to
- 4 an office in Highland Drive which was in
- ⁵ Cumberland, Rhode Island. But it was
- 6 part of the same office complex.
- ⁷ Q. Okay. But during the period
- 8 of time that you were employed at CVS
- ⁹ from 2005 to 2012 when you were in the
- 10 logistics loss prevention department as
- the director, you were physically located
- in Rhode Island, correct?
- 13 A. Yes. That's -- that's where
- my mail would come to, but I -- yes.
- 0. Okay. And that's where your
- physical office was located; is that
- 17 right?
- A. Yes, sir.
- Q. All right. I've handed you
- 20 Exhibit 132. This is a distribution
- 21 center printout for CVS Health. Can you
- tell me when you worked there, when you
- last left in 2012, approximately how many
- distribution centers were there for CVS

- 1 Health across the United States?
- MS. MILLER: Objection.
- THE WITNESS: I'm sorry, can
- 4 you rephrase the question?
- 5 BY MR. BAKER:
- Q. When you last worked at CVS
- in October of 2012, that's when you last
- 8 worked there, right?
- ⁹ A. Yes, sir.
- 0. Okay. How many distribution
- 11 centers were there for CVS? And I'm
- going to say CVS because there's so many
- different CVS entities.
- A. Right.
- Q. So when I say CVS, you know
- who I'm talking about, correct?
- A. Yes, sir.
- Q. Okay. I'm talking about
- your employer in 2012.
- So how many distribution
- centers were there at that time?
- A. I'd say, off the top of my
- head, maybe about 20.
- Q. Okay. And out of that 20,

- 1 how many were licensed for distributing
 - ² narcotics?
 - MS. MILLER: Objection.
 - THE WITNESS: If you give me
 - a moment I can try to recall.
 - Maybe about eight.
 - ⁷ BY MR. BAKER:
 - Q. Okay. Let's go through this
 - 9 list. We'll make sure I get all of them.
- 10 Okay?
- Look on this list, and
- you'll see -- you can see where it's
- 13 yellowed in on your screen. Do you see
- 14 it on the screen?
- 15 A. Yeah --
- ¹⁶ Q. Okay.
- 17 A. That's difficult for me to
- 18 read.
- 0. Okay. We'll put --
- MS. MILLER: Mr. Baker, just
- one moment.
- MR. BAKER: Sure.
- MS. MILLER: Can you tell us
- the -- I notice there's no Bates

1	number on the document.
2	MR. BAKER: This is an
3	MS. MILLER: Can you tell us
4	where this originated from?
5	MR. BAKER: This is an
6	internet document from CVS.com.
7	And this is where I got it. And I
8	want to make sure that he is able
9	to look at the yellowed-in version
10	on the screen.
11	You can pull the screen to
12	you.
13	MS. MILLER: But, Mr
14	Mr. Baker, this is as of June
15	MR. BAKER: 2014.
16	MS. MILLER: Well, it says
17	June, it's dated June 14, 2018.
18	MR. BAKER: Yeah, I'm going
19	to ask him which ones were in
20	existence when he was there.
21	MS. MILLER: Okay.
22	MR. BAKER: Okay?
23	THE WITNESS: I have
24	distance glasses that I brought

```
1
           with me.
2
    BY MR. BAKER:
3
           Q. Okay. Go ahead. All right.
4
    Let's go through it if we could.
5
           A. Can --
6
           O. Sure.
7
                 Do you want me to go get my
           Α.
8
    distance glasses?
9
           Q.
                 No. Just whatever you --
10
    you can pull the screen right --
11
                 MS. MILLER: Or the document
12
           in front of you is the same
13
           document on the screen.
14
                 THE WITNESS: Okay. Just
15
           it's difficult for me to see the
16
           yellow highlight.
17
    BY MR. BAKER:
18
           Q. Are you ready?
19
                 If I can pull the screen
           Α.
20
    closer.
21
           Q.
                 Yes.
22
                 MS. MILLER: And again,
23
           Bill, your question is as of when
```

he left --

24

1 MR. BAKER: Correct. 2 MS. MILLER: -- in 2012? 3 MR. BAKER: Correct. We're 4 going to go through that. BY MR. BAKER: 5 6 Q. All right. The first -- you 7 see where it says type Rx? That's the 8 type of distribution center. Do you see 9 that, that would be Rx licensed? 10 Α. Yes. 11 Q. Okay. All right. The first 12 one is CR, which is Conroe, Texas; is 13 that correct? 14 A. That was -- that was there, 15 yes. 16 Q. All right. Was that on 17 board in 2012? 18 A. I believe so, yes. 19 All right. The second one 0. 20 is Ennis, Texas. Do you see that? 21 Yes, correct? Α. 22 O. Was that on board as a narcotics distribution center in 2012? 23

Α.

Yes.

24

- MS. MILLER: Objection.
- ² BY MR. BAKER:
- Q. What does Rx mean to you?
- MS. MILLER: Objection.
- 5 THE WITNESS: Pharmacy.
- 6 BY MR. BAKER:
- ⁷ Q. Okay. All right. So what
- 8 do you call the type of licensing that
- ⁹ these distribution centers have when they
- are able to distribute narcotics, what do
- 11 you call that?
- MS. MILLER: Objection.
- THE WITNESS: I would call
- it a DEA registered facility.
- 15 BY MR. BAKER:
- O. Okay. A DEA registered
- ¹⁷ facility is one that distributes -- that
- has a license to distribute some form of
- ¹⁹ narcotics; is that right?
- MS. MILLER: Objection.
- THE WITNESS: It would be
- Controls III through V, I believe.
- 23 BY MR. BAKER:
- Q. Okay. Controlled Substances

III through V, correct? 1 2 A. Right. 3 Q. All right. And you know that certain controlled substances under 4 5 III were narcotics, meaning hydrocodone 6 combination products, correct? 7 MS. MILLER: Objection. 8 BY MR. BAKER: 9 O. You knew that? 10 MS. MILLER: Objection. 11 BY MR. BAKER: 12 Q. Right? 13 MS. MILLER: Objection. 14 THE WITNESS: Can you repeat 15 the question? 16 BY MR. BAKER: 17 Did you know that hydrocodone combination products were 18 19 Schedule III under the FDA? 20 MS. MILLER: Objection. 21 BY MR. BAKER: 22 Q. Did you know that? 23 MS. MILLER: Objection.

BY MR. BAKER:

24

- Q. Controlled substances. If
- they were Schedule III controlled
- ³ substances under the FDA scheduling, did
- 4 you know that?
- MS. MILLER: Objection.
- 6 BY MR. BAKER:
- ⁷ Q. When you were there in 2012?
- MS. MILLER: Objection.
- 9 THE WITNESS: At one point.
- 10 BY MR. BAKER:
- Q. Okay. I know. Did you know
- that, is what I'm asking?
- MS. MILLER: Objection.
- 14 THE WITNESS: Yes.
- 15 BY MR. BAKER:
- Q. Okay. So let's move forward
- in this list. You have Florida, Vero
- 18 Beach, Florida. Was that one of the
- 19 facilities that distributed narcotics?
- MS. MILLER: Objection.
- THE WITNESS: I would use
- the term "controls."
- 23 BY MR. BAKER:
- Q. Okay. With respect to the

- 1 next one, Indianapolis, Indiana, was that
- one of the facilities, one of the
- ³ distribution centers for CVS that
- 4 distributed controlled substances?
- ⁵ A. Yes.
- Q. Okay. Kansas City, was that
- on board when you were there or did that
- 8 open after you left?
- 9 A. I'm not aware of Kansas
- 10 City.
- 0. Okay. Move to the next
- page. New Jersey, which was Lumberton,
- New Jersey. Was that a controlled
- 14 substances distribution center for CVS
- when you were there, in Lumberton, New
- 16 Jersey?
- A. Yes.
- Q. Orlando, Florida, was that a
- 19 controlled substances distribution center
- when you were at CVS?
- 21 A. Yes.
- Q. Knoxville, Tennessee, was
- that a controlled substance distribution
- center when you were at CVS?

```
1
           Α.
                 Yes.
2
                 Patterson, California, was
           Q.
    that a controlled substance distribution
4
    center when you were at CVS?
5
           Α.
                 Yes.
6
                 North Smithfield, Rhode
7
    Island, was that a controlled substance
8
    distribution center when you were at CVS?
9
                 MS. MILLER: Mr. Baker, I'm
10
           sorry, can you tell me where you
11
           are in the document?
12
                 MR. BAKER: About at the
13
           bottom of Page 2.
14
                 MS. MILLER: Okay. Thank
15
           you.
16
                 MR. BAKER: Okay.
17
                 THE WITNESS: Can you repeat
18
           that?
19
    BY MR. BAKER:
20
                 Patterson, California, was
21
    that a controlled substances distribution
22
    center when you were at CVS?
23
           A. Yeah, I believe so, yes.
24
                Okay. North Smithfield,
           Q.
```

- 1 Rhode Island, was that a controlled
- ² substances distribution center when you
- were there at CVS?
- ⁴ A. Yes.
- O. Chemung, New York, was that
- 6 a controlled substance distribution
- ⁷ center for CVS when you were there?
- 8 A. Yes.
- ⁹ Q. Are you familiar with the
- scheduling of controlled substances
- through the Food and Drug Administration?
- MS. MILLER: Objection.
- THE WITNESS: I'm aware of
- the scheduling. I'm not -- I
- really can't recall as far as what
- might be a V, what might be a IV,
- what might be a III, what might be
- ¹⁸ a II.
- 19 BY MR. BAKER:
- Q. Do you know, if you look
- through that list that I just gave you of
- the distribution centers, there's
- different names of corporations that are
- listed as the owners of those

- distribution centers.
- 2 Do you see that on that
- 3 list?
- MS. MILLER: Objection.
- 5 BY MR. BAKER:
- 6 Q. Let's go through first,
- okay. If you start with Conroe, Texas.
- ⁸ Do you see that?
- ⁹ A. I do see that.
- Q. Okay. Do you see it says
- the DC name is CVS Pharmacy, Inc.? Do
- 12 you see that?
- 13 A. I do.
- Q. Now, if you skip down to
- 15 Florida, the Vero Beach distribution
- 16 center, it says "CVS Vero, Florida
- ¹⁷ Distribution LLC."
- Do you see that?
- A. Yes, sir.
- Q. Do you know why CVS names
- these different facilities different
- names instead of the same thing?
- A. No idea.
- MS. MILLER: Objection.

- ¹ BY MR. BAKER:
- Q. Okay. Look down below
- ³ there. It says Indiana, CVS Indiana LLC.
- Do you see that?
- ⁵ A. Yes.
- Q. Do you know why that's named
- ⁷ CVS Indiana LLC as opposed to, for
- instance, CVS Pharmacy, Inc., or CVS
- 9 Healthcare or CVS something else? Do you
- 10 know why it's named that?
- MS. MILLER: Objection.
- THE WITNESS: No.
- 13 BY MR. BAKER:
- Q. Was there any strategy that
- you're aware of at CVS for naming these
- 16 facilities different corporate names like
- 17 that?
- MS. MILLER: Objection.
- THE WITNESS: It wasn't my
- responsibility.
- 21 BY MR. BAKER:
- Q. Okay. If you look at the
- Lumberton, New Jersey one on the second
- 24 page. It lists that as owned by CVS


- ¹ Pharmacy, Inc.
- Do you see that?
- A. Yes.
- O. Okay. If you look at
- ⁵ Chemung, New York. Look at the bottom of
- Page 2. It says it's owned by CVS Rx
- ⁷ Services, Inc. Do you know why that
- 8 exists like that, as opposed to being
- 9 owned by CVS Pharmacy, Inc., or another
- 10 CVS entity?
- MS. MILLER: Objection.
- THE WITNESS: No.
- 13 BY MR. BAKER:
- Q. When you were working there
- last, at CVS, in 2012, which CVS entity
- issued your paycheck?
- A. I can't recall. I had
- direct deposit.
- O. All right. From the time
- that you worked at CVS from 2005 to 2012
- in the department of logistics loss
- 22 prevention, were you involved with the
- suspicious order monitoring program of
- 24 CVS?


- A. First off, the department I
- ² actually worked in would be the loss
- ³ prevention department.
- Q. I understand that. My
- ⁵ question was, were you involved with the
- 6 suspicious order monitoring program?
- A. During a period of time,
- ⁸ Yes, I was.
- 9 Q. Okay. And did that start in
- ¹⁰ 2008?
- MS. MILLER: Objection.
- THE WITNESS: No. I believe
- it would have been earlier than
- that.
- 15 BY MR. BAKER:
- Q. Okay. When did you first
- start getting involved in the suspicious
- order monitoring program at CVS?
- 19 A. I believe it may have been
- ²⁰ around 2007.
- O. Okay. Was that when you
- were involved with the initial drafts of
- the suspicious order monitoring policy
- ²⁴ and procedure?


```
1
                  MS. MILLER: Objection.
2
                  THE WITNESS: Can you repeat
3
            that, please?
4
    BY MR. BAKER:
5
                  Was that when you started to
            0.
6
    get involved with the suspicious order
7
    monitoring policy and procedure drafts?
8
                  MS. MILLER: Objection.
                  THE WITNESS: I would have
9
10
            been involved in that.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```


```
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
    BY MR. BAKER:
22
                    Okay. During the time that
             Q.
23
    you were involved in loss prevention at
24
    CVS, what sort of losses were you trying
```


```
1
    to prevent?
2
                 MS. MILLER: Objection.
3
                 THE WITNESS: So job
4
           responsibilities or?
5
    BY MR. BAKER:
6
              What were you trying to
7
    prevent the loss of?
8
                 The position was to protect
9
    the, you know, people, assets --
10
           O. At the time --
11
           A. -- of the company.
12
                 MS. MILLER: If you can just
13
           let him finish. Thank you.
14
    BY MR. BAKER:
15
           O. As it relates to the
    distribution of narcotics out of the
16
17
    distribution centers, what was your
18
    involvement with the suspicious order
19
    monitoring process in relation to those
20
    narcotics?
21
                 MS. MILLER: Objection.
22
                 THE WITNESS: I'm not sure I
23
           understand your question.
24
    BY MR. BAKER:
```



































```
1
2
                  MS. MILLER: Objection.
3
                  MR. BAKER: Pull up
4
           Exhibit 64 please.
5
                  (Document marked for
6
           identification as Exhibit
7
           CVS-Devlin-P-64.)
8
    BY MR. BAKER:
9
           Q. I'd like you to pull up
10
    hydrocodone, which is the second page.
11
                 Would I be able to take a
           Α.
12
    break?
13
           Q. Do you need to go to the
14
    bathroom?
15
                 I do.
           Α.
16
                  MR. BAKER: Okay. Sure. Go
17
           ahead.
18
                 MS. MILLER: Go off the
19
           record.
20
                  THE VIDEOGRAPHER: Going off
21
           the record. The time is 9:20.
22
                  (Short break.)
23
                  THE VIDEOGRAPHER: We are
24
           going back on record. Beginning
```


- of Media File Number 2. The time
- is 9:30.
- 3 BY MR. BAKER:
- ⁴ Q. You have in front of you the
- 5 DEA drug fact sheet.
- Do you see that?
- A. Yes, sir.
- Q. Okay. It lists hydrocodone.
- 9 It says, "Hydrocodone is the most
- 10 frequently prescribed opioid in the
- ¹¹ United States."
- Do you see that?
- 13 A. No.
- MS. MILLER: Bill, can you
- direct him to a page?
- 16 BY MR. BAKER:
- Q. Okay. Go to the second page
- of your DEA drug fact sheet. If you look
- on the monitor, it's right in front of
- ²⁰ you.
- Do you see it?
- A. It's easier for me to look
- 23 at the paper.
- Q. Do you see where it says


```
1
    "hydrocodone" at the top?
2
           Α.
                 Yes.
3
                 Okay. Do you see where it
4
    says, "Hydrocodone is the most frequently
5
    prescribed opioid in the United States
6
    and is associated with more drug abuse
7
    and diversion than any other illicit
8
    (sic) or illicit opioid."
9
                 Do you see that?
10
           Α.
                 Yes.
11
                 Okay. Did you know this
12
    before it was read to you today by
13
    looking at this DEA drug fact sheet?
14
                 MS. MILLER: Objection.
15
    BY MR. BAKER:
16
                 Did you know this?
           Q.
17
                 MS. MILLER: Objection.
18
                  THE WITNESS: Hydrocodone,
19
           per se, I'm not sure.
20
    BY MR. BAKER:
21
                 Okay. Did the distribution
22
    centers over which you were the logistics
23
    director -- director of logistics and
24
    loss prevention, distribute hydrocodone
```


```
combination products?
1
2
                 I believe so.
           Α.
3
           Q.
                 Okay. Do you know those to
4
    be opioids?
5
                 MS. MILLER: Objection.
6
                 THE WITNESS: Not at the
7
           time.
8
    BY MR. BAKER:
9
             Okay. Do you know it now?
           0.
10
           Α.
                 Now?
11
                 Do you know that now?
           Q.
12
                 After reading, seeing this,
           Α.
13
    yes.
14
                 Okay. Have you ever heard
           Ο.
    of the opioid crisis?
15
16
                 I have recently heard of it,
17
    yes.
18
           Q. Did you know about it to be
19
    in existence which you were employed at
20
    CVS?
21
                 MS. MILLER: Objection.
22
                 THE WITNESS:
                                No.
23
    BY MR. BAKER:
24
                 That was never discussed
           Q.
```


- with anybody at CVS, the opioid crisis or
- the nature of the opioid crisis going on
- 3 from 2005 to 2012 when you were in loss
- ⁴ prevention logistics?
- MS. MILLER: Objection.
- 6 BY MR. BAKER:
- ⁷ Q. That was never discussed?
- MS. MILLER: Objection.
- 9 THE WITNESS: No, not that I
- can recall.
- 11 BY MR. BAKER:
- Q. Did you ever attend any DEA
- meetings of any type, any DEA conferences
- of any type?
- A. Not that I can recall.
- Q. Did you ever attend any
- training on the opioid crisis while you
- were at CVS in logistics and loss
- ¹⁹ prevention?
- A. No, not that I recall.
- MR. BAKER: Okay. Go to
- Exhibit Number 58.
- MS. MILLER: I don't think
- we have Exhibit 58.


```
1
                   MR. BAKER: Don't have 58?
2
            Go to exhibit 102.
3
                   MS. MILLER: Is that a new
4
            exhibit, Bill?
5
                   MR. BAKER: Yeah, Exhibit
6
            102.
7
                   MS. MILLER: Is that a new
8
            one?
9
                   MR. BAKER: Yes.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```






























































































































_	
1	
2	
3	
4	
5	
6	
7	
8	MR. BAKER: Okay. I've been
9	going about an hour and a half
10	myself. And I have not taken a
11	break. So I'm going to take about
12	a five-minute break.
13	THE VIDEOGRAPHER: We're
14	going off the record. The time is
15	10:09.
16	(Short break.)
17	THE VIDEOGRAPHER: We are
18	going back on record. Beginning
19	of Media File 3. The time is
20	10:20.
21	BY MR. BAKER:
22	Q. Okay. We're back on the
23	record looking at Exhibit Number 87,
24	which was the


```
MS. MILLER: Bill, you mean
1
2
              97?
3
     BY MR. BAKER:
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```













```
1
2
3
4
    BY MR. BAKER:
5
6
                 Okay. You know hydrocodone
7
    combination products are narcotics. I
8
    showed you the drug fact sheets on that,
9
    correct?
10
                  MS. MILLER: Objection.
11
    BY MR. BAKER:
12
           Q. You know that, don't you?
13
                  MS. MILLER: Objection.
14
                  THE WITNESS: After reading
15
           the -- you know, according to that
16
           fact sheet, that's what it's
17
           classified as.
18
    BY MR. BAKER:
19
                 And you know they're
20
    opioids, correct?
21
                  MS. MILLER: Objection.
22
                  THE WITNESS: I mean --
23
    BY MR. BAKER:
24
                  I mean, that's what it said.
```


```
You just read it.
1
2
                 MS. MILLER: Objection.
3
                 THE WITNESS: Well, again,
4
           according to the sheet you sent
5
           me, yes.
6
    BY MR. BAKER:
7
                 Well, listen, what color is
           0.
8
    that pen right there?
9
                 MS. MILLER: Objection.
10
    BY MR. BAKER:
11
           Q. What color is it?
12
                 MS. MILLER: Objection.
13
                 THE WITNESS: You're not
14
           going to buy this, but I am
15
           color-blind.
16
    BY MR. BAKER:
17
           Q. Okay. Well, what's in this
18
    glass right here?
19
                 MS. MILLER: Objection.
20
    BY MR. BAKER:
21
                 Does it look like water?
           Q.
22
                 MS. MILLER: Mr. Baker.
23
    BY MR. BAKER:
           Q. See, I want to ask direct
24
```


- questions and get direct answers. But
- every time I ask you a question, you kind
- of, well, I don't remember, this, that.
- ⁴ I just want to know what the facts are.
- ⁵ Okay. And I don't want to dance around
- ⁶ with you with questions and answers. I
- ⁷ just want to know the facts. Okay. And
- 8 I'm not trying to ask you trick
- ⁹ questions.
- So if you can answer my
- 11 questions directly, we can get through
- this much smoother than what you're
- 13 allowing. Okay?
- MS. MILLER: Bill, he's
- answering your questions.
- 16 BY MR. BAKER:
- Q. So let me -- let me repeat
- the question. Let's go back.
- A. My -- my intention is to
- answer your question, sir.
- O. Okay. You know, you know
- that hydrocodone combination products are
- opioids, correct?
- MS. MILLER: Objection.


```
1
           Asked and answered.
2
                  THE WITNESS: According to
            the sheet you provided me, that's
3
4
           what it states.
    BY MR. BAKER:
5
6
              Okay. Did you know that a
7
    hydrocodone combination product was an
8
    opioid when you worked at CVS?
9
                  I -- as I previously
    testified, I would refer to it as a
10
11
    control drug.
12
                  Okay. Did you know it was
            Q.
13
    an opioid?
14
            Α.
                  No.
15
16
17
18
19
20
21
22
23
24
```




























```
1
                    It says, "Responsibilities.
2
            Q.
    DC Rx." What is a DC Rx?
3
4
                    I believe that would be DC
            Α.
5
    pharmacy.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```
































































```
1
    BY MR. BAKER:
2
           O. Go ahead.
                  MS. MILLER: Go ahead and
3
4
           answer.
5
                  THE WITNESS: That -- that
6
           would be within the ballpark.
7
    BY MR. BAKER:
8
           Q. Okay. And do you know why
    it was moved from a distribution
9
10
    center-related program to Knoxville at
11
    that time?
12
                  MS. MILLER: Objection.
13
           Asked and answered.
14
    BY MR. BAKER:
15
                 Do you know?
           0.
16
                  I believe I -- I had
           Α.
17
    mentioned from a -- you know, the
18
    continuous evolution of the process and
19
    from an operational efficiency
20
    standpoint.
21
22
23
24
```


















```
1
2
3
4
5
6
7
8
9
10
11
12
                  What was your involvement
            Q.
13
    with respect to the IRRs and the review
14
    of the IRRs, if anything, while you were
15
    at CVS?
16
                  I was not involved in the
           Α.
17
    day-to-day review of the IRR.
18
              What was your involvement
19
    with respect to management of how many
20
    people would review IRRs?
21
                  I would be involved in the
22
    decision as far as how many people would
23
    review the IRR.
24
                  Okay. And that was from
            Q.
```


```
what period to what period that you were
1
2
    involved in making that decision?
3
                   It would probably be from
4
    the beginning of the process till I left.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```











































































```
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
                  Okay. During the time that
           Q.
16
    you were there --
17
                  MR. BAKER: Let's take a
           break for just one second. I've
18
19
           got to --
20
                  MS. MILLER: Can we actually
21
           take -- I think we've been going
22
           for a while. Can we take a little
23
           bit of a break?
24
                  MR. BAKER: Okay. Do you
```


```
1
            want to take a little bit of a
2
            break?
3
                  MS. MILLER: Yeah.
4
                  MR. BAKER: Okay.
5
                   THE VIDEOGRAPHER: Off the
6
            record. 11:32.
7
                   (Short break.)
8
                   THE VIDEOGRAPHER: Back on
9
            record. Beginning Media File
10
            Number 5. The time is 11:48.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```







































































































































```
1
           time to break for lunch. Do you
2
           want to try to take, what,
3
           30 minutes?
4
                 THE WITNESS: Ten minutes?
5
                 MR. BAKER: For lunch?
6
                 MS. MILLER: No. 30 minutes
7
           would be great.
8
                  THE VIDEOGRAPHER: Off the
9
           record. The time is 12:29.
10
                  (Lunch break.)
11
                  THE VIDEOGRAPHER: We're
12
           going back on record. Beginning
13
           of Media File Number 6. The time
14
           is 1:14.
15
    BY MR. BAKER:
16
           Q. Mr. Devlin, we just took a
17
    lunch break, correct?
18
           A. Yes.
19
20
21
22
23
24
```























































































































































































```
1
2
                  Okay. Let's take a break
    while we find that.
4
                  THE VIDEOGRAPHER: Off
            video, 2:07.
5
6
                  (Short break.)
7
                  THE VIDEOGRAPHER: We are
8
            going back on record. Beginning
            of Media File 8. The time is
9
10
            2:21.
11
    BY MR. BAKER:
12
                  Pull Exhibit 81, please.
13
    You have in front of you --
14
                  MS. MILLER: Could you give
15
           us one minute?
16
                  MR. BAKER: Sure.
17
                  MS. MILLER: Okay.
18
19
20
21
22
23
24
```


























































































































































```
1
           quick break? A quick --
2
                  MR. BAKER: Somebody need to
3
           go to the bathroom or --
4
                  MS. MILLER: I would like to
5
           if we could.
6
                  MR. BAKER: Okay. Go ahead.
7
                  THE VIDEOGRAPHER: Going off
8
           the record. The time is 3:00 p.m.
9
                  (Short break.)
10
                  THE VIDEOGRAPHER: We are
11
           going back on the record.
12
           Beginning of Media File 9. The
13
           time is 3:11.
14
15
16
17
18
19
20
21
22
23
24
```













































































```
1
           so?
2
                  MR. BAKER: No, I just need,
3
           like, two or three. I mean, if
           y'all need more than that -- I'm
4
5
           just, you know, going to sit here
6
           and take a look at my notes.
7
                  THE WITNESS: If you don't
8
           mind, I'm going to take a couple
9
           minutes.
10
                  THE VIDEOGRAPHER: Going off
11
           the record. The time is 3:33.
12
                  (Short break.)
13
                  THE VIDEOGRAPHER: We are
14
           going back on the record.
15
           Beginning of Media File 10. The
16
           time is 3:43.
17
18
                    EXAMINATION
19
20
    BY MR. DeROCHE:
21
                 Mr. Devlin, my name is Jim
22
    DeRoche. I have some hopefully brief
    follow-up questions for you.
23
24
                  First of all, where do you
```

- 1 reside now again? I didn't hear that.
- A. I live in Pocasset, in
- ³ Massachusetts.
- Q. Okay. Is that a suburb of
- 5 Boston of some sort?
- 6 A. It's actually part of Cape
- $7 \quad \text{Cod.}$
- Q. A-ha. Okay.
- 9 When did you come to
- 10 Washington?
- A. When did I come to
- Washington?
- 0. Yeah.
- A. I arrived -- let's see,
- today is Thursday, right?
- Q. Correct.
- A. Yeah, I arrived on Tuesday.
- Q. You arrived on Tuesday?
- ¹⁹ A. Yes.
- Q. Okay. And what were you
- doing for -- since -- between Tuesday and
- today?
- 23 A. I had some --
- MS. MILLER: Objection.

- 1 BY MR. DeROCHE: 2 Excuse me? I didn't hear what you said. 4 MS. MILLER: Go ahead. 5 BY MR. DeROCHE: 6 You can answer the question, 0. 7 sir. 8 I -- I had some prep time. Α. 9 So you prepared for this 10 deposition? 11 Α. Yes. 12 Okay. You met with lawyers 0. 13 here at the office we're sitting in; is 14 that correct? 15 A. Yes. 16 Q. And you met on -- did you 17 meet on Tuesday or did you arrive late 18 Tuesday? 19 Briefly Tuesday. 20 And then you met on 21 Wednesday as well, spent all day here? 22 MS. MILLER: Objection.
- 23 BY MR. DeROCHE:
- Q. You can answer.

- A. Most of the day.
- Q. Okay. You looked at
- 3 documents?
- A. Some documents, yes.
- ⁵ Q. Okay. You have an
- 6 understanding of what this case is about,
- ⁷ correct?
- MS. MILLER: Objection.
- 9 THE WITNESS: Not -- not in
- any great detail. I mean high
- level. High level, but there's a
- lot more I don't know than I do
- 13 know.
- 14 BY MR. DeROCHE:
- Q. Sure. I think that applies
- 16 to most of us.
- When did you find out that
- you were being deposed in connection with
- 19 this case?
- A. Early December maybe.
- Q. Okay. So you've known for
- 22 approximately a month that your
- deposition was going to be taken?
- A. About that, yeah.

- Q. Did you talk to any folks
- ² from CVS who you used to work with, about
- 3 this deposition?
- ⁴ A. No.
- ⁵ Q. Other than the lawyers, have
- ⁶ you spoken to anybody else?
- A. My wife knows I'm here.
- Q. Other than her, no one else?
- ⁹ A. My son and daughter know I'm
- 10 here.
- 0. Other than family, no
- other -- no other individuals?
- A. That's about it.
- Q. Okay. So you didn't try to
- reach out to folks you used to work with,
- 16 like Ms. Hinkle or --
- ¹⁷ A. No.
- Q. -- anybody else?
- ¹⁹ A. No.
- Q. Judy Hughes?
- ²¹ A. No. No.
- Q. Do you stay in contact with
- any people from CVS that you used to work
- 24 with?

```
1
                 Very few, but just an
           Α.
2
    occasional hello. But not -- like I
    really haven't seen people that I worked
    with from CVS or -- so...
5
           Q. Did you leave on good terms
6
    in your view?
7
                 MS. MILLER: Objection.
8
                 THE WITNESS: I mean I left
9
           on my own.
10
    BY MR. DeROCHE:
11
             You don't have any animosity
12
    towards CVS?
13
                 MS. MILLER: Objection.
14
                 THE WITNESS: No. It was an
15
           opportunity to be involved in a
16
           lot of, you know, a lot of
17
           responsibility and a lot of
18
           project management work. And I
19
           think professionally it was a good
20
           opportunity, and at the time a
21
           better opportunity developed.
22
    BY MR. DeROCHE:
23
           Q. Sure. Do you have clients
    in Washington DC that you came to see or
24
```

- did you just come for this deposition?
- A. I came for the deposition.
- Q. So since Tuesday, you
- 4 focused on this deposition that we're
- 5 having here today?
- A. I've gone and -- getting
- back to the hotel room, I've done some
- 8 work for other clients.
- 9 Q. Okay. All right. I want to
- try to understand where logistics loss
- prevention fit in the -- in the hierarchy
- of CVS. I don't think I understand that
- 13 at all.
- So can you explain logistics
- loss prevention and where it fit in, in
- 16 terms of -- of the structure at CVS?
- 17 A. Sure. I was -- so I was a
- part of the overall loss prevention
- department. And there is a field loss
- 20 prevention department which would focus
- on stores. There was logistics loss
- prevention which focused, supported
- distribution centers. There is also some
- corporate support around loss prevention

- ¹ also. And I believe there also was some
- loss prevention support for some of the
- 3 Caremark mail order sites when I was
- ⁴ present.
- ⁵ Q. Okay. And so logistics loss
- 6 prevention focused primarily on the
- 7 distribution centers?
- 8 A. That was -- that was a --
- ⁹ you know, a big component. I also
- provided some support to some of the
- 11 Caremark mail order sites from a safety
- 12 standpoint.
- 0. That was under loss --
- 14 logistics loss prevention as well?
- A. It was.
- O. Other than the safety
- that -- oversight that you may have
- 18 provided to the Caremark mail order
- division, otherwise besides that, you did
- focus on the distribution centers?
- A. That was my primary focus.
- ²² I mean I had a variety of
- responsibilities during my career.
- Some -- some retail, some corporate. But

- ¹ I always had the distribution centers as
- ² a main part of what I was doing.
- Q. And when you took over as
- 4 director of logistics loss prevention,
- were you sort of the top dog in the
- 6 logistics loss prevention department?
- A. I managed the department,
- 8 so...
- 9 O. And that was at least since
- 10 2005 you had held that position?
- 11 A. Yeah, again as I testified
- earlier, I mean there's typical --
- 13 typical corporate America. I mean --
- 0. Sure.
- 15 A. -- you can have same title
- but different levels.
- 0. Great.
- A. So, you know, I was a
- director level different in 2005 than say
- ²⁰ a director level I was in, say, 2003.
- But it was just a -- you know, it was
- kind of an evolution as the company
- 23 continued to grow and even some of my
- responsibilities grew.

```
Q. So the director level that
```

- you attained in 2005 was, was that the
- 3 highest level -- director level --
- ⁴ A. No.
- 5 Q. -- in logistics loss
- 6 prevention?
- 7 MS. MILLER: Give him a
- 8 chance to finish his question,
- 9 please.
- THE WITNESS: Oh, sorry.
- 11 BY MR. DeROCHE:
- Q. Highest level in logistics
- loss prevention.
- 14 A. There are -- you know, I
- 15 guess I was the director of logistics,
- loss prevention. As far as my position
- qoes on the director level, I was
- probably in the middle of the levels of
- directors, like there could have -- you
- 20 know, there could have been another --
- there could have been -- like I could
- have attained another higher level of
- director and still be in logistics, loss
- ²⁴ prevention.

```
But there wasn't -- you
```

- know, I certainly reported in to someone
- ³ else. But that individual had, you know,
- ⁴ other responsibilities.
- ⁵ Q. You reported to Judy Hughes,
- ⁶ I think you said; is that correct?
- ⁷ A. Yes.
- Q. And was Ms. Hughes also
- 9 considered a director of logistics loss
- prevention or did she have some other
- 11 title?
- 12 A. I believe she was just
- director of loss prevention.
- 0. Okay. She was -- so
- 15 logistics loss prevention is a department
- within loss prevention?
- A. It is. It is.
- Q. She was at the loss
- 19 prevention level, as opposed to the
- logistics loss prevention level?
- MS. MILLER: Frank, just
- give him a chance --
- MR. DeROCHE: Yeah, sure.
- MS. MILLER: -- so you're

```
not stepping on him.
1
2
    BY MR. DeROCHE:
3
                  Trying to get a distinction
4
    so I understand. So in terms of
    directors of logistics, loss prevention,
5
6
    you were -- you were the top person of
7
    logistics, loss prevention as of 2005?
8
                  MS. MILLER: Objection.
9
    BY MR. DeROCHE:
10
           Q. Is that correct?
11
                  My title was director of
           Α.
12
    logistics, loss prevention.
13
14
15
16
17
18
19
20
21
22
23
24
```

```
1
2
3
4
5
6
7
8
9
10
11
    BY MR. DeROCHE:
12
                  Sure. I understand.
            Q.
13
    Everyone needs got a boss.
14
                  Right. And even -- you
           Α.
15
    know, and --
16
           Q. At least at home, but be
17
    that as it may.
18
                  Even, like, my business card
19
    would say director of logistics loss
20
    prevention. You know, from a -- I guess
21
    a budgetary payroll standpoint, it may
22
    just say director loss prevention.
23
    Director 1 or Director 2. CVS was big --
    changed, you know, grading systems and
24
```

- ¹ whatnot so.
- O. I understand it was a
- multi-billion dollar company at the time
- 4 that you were there. Probably even
- ⁵ bigger now.
- MS. MILLER: Objection.
- ⁷ BY MR. DeROCHE:
- ⁸ Q. So there was many levels of
- 9 corporate structure, I would assume, that
- you had to answer through?
- MS. MILLER: Objection.
- 12 THE WITNESS: Can you repeat
- that?
- 14 BY MR. DeROCHE:
- 0. Did you have -- let's put it
- this way. Logistics, loss prevention,
- did you have a budget?
- A. Yes.
- Q. And you were ultimately
- responsible for budget issues, I take it,
- 21 as the director?
- A. For my piece of the pie.
- Q. Right.
- A. The overall loss prevention

- budget, I was tasked with managing that.
- Q. Okay. You knew that at
- least with respect to the Rx distribution
- 4 centers, that they had a license that was
- issued by the Drug Enforcement Agency,
- 6 correct?
- ⁷ A. Yes.
- ⁸ Q. And were you responsible as
- ⁹ director of logistics, loss prevention in
- ensuring that those licenses were
- 11 maintained?
- MS. MILLER: Objection.
- THE WITNESS: I'm not sure
- quite what you mean by maintained.
- 15 BY MR. DeROCHE:
- Q. Excuse me?
- 17 A. I'm not quite sure what you
- mean by maintained.
- 19 O. That each of the -- each of
- the Rx distribution centers continued to
- 21 be licensed by the Drug Enforcement
- 22 Agency to distribute controlled
- ²³ substances.
- MS. MILLER: Objection.

```
1
                 THE WITNESS: There was a --
2
           you know, people responsible for
3
           licensing and registration within
4
           company.
5
    BY MR. DeROCHE:
6
                 Okay. So logistics loss
7
    prevention didn't handle that?
8
                 No. Like if you, like to
           Α.
9
    renew a DEA license, I wouldn't be
10
    involved in that.
11
                 Okay. What about complying
12
    with the conditions upon which that
13
    license is issued?
14
                 MS. MILLER: Objection.
15
                 THE WITNESS: It could be
16
           maybe certain components, but
17
           not -- not full responsibility for
18
           all of it.
19
    BY MR. DeROCHE:
20
                 Okay. The component -- one
           0.
21
    of the components -- one of the
22
    conditions, I like to call it, to the
23
    license is that the distribution centers
24
    design and maintain a system to identify
```

- suspicious orders?
- MS. MILLER: Objection.
- 3 BY MR. DeROCHE:
- ⁴ Q. You're aware of that, right?
- MS. MILLER: Objection.
- THE WITNESS: As per the --
- yes.
- 8 BY MR. DeROCHE:
- 9 Q. Okay. And you understood
- that there was, in fact, a division
- within the DEA that was called the
- department of diversion that focused on
- the diversion of controlled drugs from
- the legal use of those drugs. You're
- aware that there's a diversion
- department?
- A. I wouldn't necessarily use
- that term. I mean, just -- to me, the
- 19 DEA was the DEA.
- Q. Well, they sent diversion
- investigators at times to inspect --
- A. Right, right.
- Q. Right. So you know --
- 24 A. But we just -- we always

```
<sup>1</sup> just said the DEA is here.
```


- Q. DEA is showing up, knocking
- on the door?
- A. Right. We didn't I guess
- ⁵ formally get into the exact title. It
- 6 was just, the DEA is here.
- ⁷ Q. And you understood that the
- 8 concern of DEA was that controlled
- ⁹ substances like hydrocodone combination
- products not be diverted into street
- drugs, for lack of a better term, right?
- MS. MILLER: Objection.
- 13 BY MR. DeROCHE:
- Q. You understood that, right?
- MS. MILLER: Objection.
- THE WITNESS: I mean, I
- looked at my role to ensure the
- safety and security of control
- drugs, you know, upon receipt into
- the distribution center, and then
- to upon delivery to the CVS retail
- store.
- 23 BY MR. DeROCHE:
- Q. Except the retails -- well,


- part of the responsibility as you've been
- ² talking about all day today, for a
- distribution center, was to ensure that
- 4 orders were legitimate orders that
- ⁵ weren't going to lead to diversion.
- 6 You're aware of that?
- MS. MILLER: Objection.
- 8 THE WITNESS: Again, I think
- ⁹ I spoke earlier. I was protecting
- the integrity, you know, from a
- security, safety standpoint and to
- ensure that they are, you know,
- falling into the proper hands.
- 14 BY MR. DeROCHE:
- O. Correct. Because if they
- 16 fall into the -- not the proper hands,
- again you have things like an epidemic of
- opioid use of prescription drugs.
- MS. MILLER: Objection.
- 20 BY MR. DeROCHE:
- Q. And obviously you don't want
- that, right?
- MS. MILLER: Objection.
- THE WITNESS: No. I mean,


```
1
           my -- my focus really was, you
2
           know, during my time there, I
3
           mean, it was, you know, preventing
4
           theft. I mean, that was, you
5
           know -- as far as other terms or
6
           whatnot, it was just, you know, we
7
           discussed, you know, how to ensure
8
           the safety and security of the
9
           control drugs.
10
    BY MR. DeROCHE:
11
           Q. I understand that, you know,
12
    theft can be one component by which drugs
13
    are diverted. But you recognize, don't
14
    you, and didn't you recognize at the
15
    time, that diversion could occur through
16
    other means besides theft?
17
                 MS. MILLER: Objection.
18
           Asked and answered.
19
                 THE WITNESS: Ultimately,
20
           it's theft.
21
    BY MR. DeROCHE:
22
                 Even if the drugs are paid
           0.
23
    for to CVS?
24
                 MS. MILLER: Objection.
```


```
1
                 THE WITNESS: I quess part
2
           of it would be a case-by-case
3
           basis. You would have to look at
4
           how was it paid for. Was it, you
5
           know, a legitimate prescription.
6
           I mean, there's a lot -- a lot
7
           goes into it. I've always, you
8
           know shied away from just blanket
9
           statements.
10
    BY MR. DeROCHE:
11
           0.
                 Sure.
12
                 I mean, just -- each
           Α.
13
    situation, it's separate and, you know,
14
    you have to evaluate the facts.
15
                 Sure. There could be
           Ο.
16
    varying ways through which drugs are
17
    diverted besides theft. You just
18
    mentioned one, illegitimate prescription.
19
    Even if it's brought in, filled, and the
20
    full price is paid to CVS, that could be
21
    an instance of diversion, just like if
22
    someone stole it off the shelf. You
23
    agree with that, right?
24
                 MS. MILLER: Objection.
```


```
1
                 THE WITNESS: Again, I come
2
           back to, you know, having -- I'm
3
           responsible to protect the
4
           controls and the safety and
5
           security and make sure they fall
6
           into the proper hands. I mean,
7
           that's -- that's the ultimate
8
           qoal.
9
    BY MR. DeROCHE:
10
                 Right. And that was one of
11
    the conditions to the distribution
12
    centers getting their license from the
13
    DEA to distribute these drugs, is that
14
    CVS played by the rules and did its part
15
    to police and prevent diversion of those
16
    drugs?
17
                 MS. MILLER: Objection.
18
    BY MR. DeROCHE:
19
           Q. You would agree, right?
20
                 You know, I -- you know, I
           Α.
21
    guess when I was involved I was, you
22
    know, certainly to ensure we were meeting
23
    the requirements of the DEA regulations.
24
    I mean that's -- that's what, you know,
```











































```
1
2
3
4
5
6
7
8
9
10
11
12
13
                  Okay. And in terms of the
            Ο.
14
    use of the PDMR, was there any kind of
15
    written policy that incorporated the PDMR
16
    into any kind of system to identify
17
    suspicious orders?
18
                  I don't recall the PDMR
19
    procedures. It's not a system that I
20
    used or I was familiar with, so I --
21
                  Your answer is no?
            Q.
22
                  I really couldn't answer
            Α.
23
    that.
24
```



















```
1
                  Okay. Are you familiar with
            Q.
    a gentleman named Terrence Dugger?
2
3
                  Yes.
            Α.
4
            Q. Okay. And what was
5
    Mr. Dugger?
6
                  He was a loss prevention
            Α.
7
    manager.
8
                  At the Indianapolis DC?
            Q.
9
            Α.
                   At the time, yes.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```






































































































































































```
1
                  (Short break.)
2
                  THE VIDEOGRAPHER: Going
3
           back on record. Beginning of
4
           Media File Number 12. The time is
5
           5:40.
6
                  MR. DeROCHE: Thank you for
7
           your time. We have nothing
8
            further.
9
                  THE VIDEOGRAPHER: No
10
           questions?
11
                  MS. MILLER: No questions.
12
           Thank you.
13
                  THE VIDEOGRAPHER: This
14
           concludes today's deposition.
15
           We're going off the record. The
16
           time is 5:40.
17
                  (Excused.)
18
                  (Deposition concluded at
19
           approximately 5:40 p.m.)
20
21
22
23
24
```

```
1
2
                    CERTIFICATE
3
4
5
                  I HEREBY CERTIFY that the
    witness was duly sworn by me and that the
6
    deposition is a true record of the
    testimony given by the witness.
7
                  It was requested before
8
    completion of the deposition that the
    witness, FRANK DEVLIN, have the
9
    opportunity to read and sign the
    deposition transcript.
10
11
12
           MICHELLE L. GRAY,
           A Registered Professional
13
           Reporter, Certified Shorthand
           Reporter, Certified Realtime
14
           Reporter and Notary Public
           Dated: January 15, 2019
15
16
17
                  (The foregoing certification
18
    of this transcript does not apply to any
    reproduction of the same by any means,
19
20
    unless under the direct control and/or
21
    supervision of the certifying reporter.)
22
23
2.4
```

1 INSTRUCTIONS TO WITNESS 2 3 Please read your deposition 4 over carefully and make any necessary 5 corrections. You should state the reason 6 in the appropriate space on the errata 7 sheet for any corrections that are made. 8 After doing so, please sign 9 the errata sheet and date it. 10 You are signing same subject 11 to the changes you have noted on the 12 errata sheet, which will be attached to 13 your deposition. 14 It is imperative that you 15 return the original errata sheet to the deposing attorney within thirty (30) days 16 17 of receipt of the deposition transcript 18 by you. If you fail to do so, the 19 deposition transcript may be deemed to be 20 accurate and may be used in court. 21 22 23 24

Case: 1:17-md-02804-DAP Doc.#: 2173-17 Filed: 08/12/19 488 of 490 PageID.#: 308342 Highly Confidential - Subject to Further Confidentiality Review

1		
		ERRATA
2		
3		
4	PAGE LINE	CHANGE
5		
6	REASON:	
7		
8	REASON:	
9		
10	REASON:	
11		
12	REASON:	
13		
14	REASON:	
15		
16	REASON:	
17		
18	REASON:	
19		
20	REASON:	
21		
22	REASON:	
23		
24	REASON:	

Case: 1:17-md-02804-DAP Doc#: 2173-17 Filed: 08/12/19 489 of 490 PageID #: 308343 Highly Confidential Example to Further Confidential Example Review

1					
2	ACKNOWLEDGMENT OF DEPONENT				
3					
4	I,, do				
5	hereby certify that I have read the				
6	foregoing pages, 1 - 490, and that the				
7	same is a correct transcription of the				
8	answers given by me to the questions				
9	therein propounded, except for the				
10	corrections or changes in form or				
11	substance, if any, noted in the attached				
12	Errata Sheet.				
13					
14					
15					
16	FRANK DEVLIN DATE				
17					
18					
19	Subscribed and sworn				
	to before me this				
20	, day of, 20				
21	My commission expires:				
22					
					
23	Notary Public				

Case: 1:17-md-02804-DAP Doc.#: 2173-17 Filed: 08/12/19 490 of 490 PageID.#: 308344 Highly Confidential ty Review

1			LAWYER'S NOTES
2	PAGE	LINE	
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			